Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NanoViricides Inc
NNVC | US
1.47
USD-0.01
-0.68%
NNVC | US
About NanoViricides Inc
Sector
Healthcare
Industry
Drug Manufacturers - Major
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.47
Open
1.52
High
1.52
Low
1.42
NanoViricides Inc. a nano-biopharmaceutical research and development company discovers develops and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide an escape-resistant anti-HIV nanoviricide. In addition it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton Connecticut.
View LessNNVC | US
Risk
66.0
Sharpe
0.20
Luna's Score
42/100
Recommendation
Sell
Luna says (NNVC | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
68.8%1 month
66.0%3 months
88.3%6 months
132.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.91
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-1.11
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-7.76M
MarketCap
21.58M
MarketCap(USD)
21.58M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-63.00
Short ratio
3.01
Short perc.
3.20
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.21
Range1M
0.31
Range3M
1.22
Volumes: Market Activity
Rel. volume
0.53
Price X volume
150.55K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.11 | 21.06 | Cheaper |
| Ent. to Revenue | - | 5.64 | - |
| PE Ratio | - | 41.17 | - |
| Price to Book | 1.91 | 11.46 | Cheaper |
| Dividend Yield | - | 3.27 | - |
| Std. Deviation (3M) | 88.29 | 39.12 | Riskier |
| Debt to Equity | - | 1.72 | - |
| Debt to Assets | - | 0.31 | - |
| Market Cap | 21.58M | 200.67B | Emerging |
